Table 1 The basic characteristics of the included studies
From: The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis
study | Agent type | Treatment arms | Dosage of angiogenesis inhibitors | Patients' status | Sample size | Median age | Median duration of follow-up (mo) |
|---|---|---|---|---|---|---|---|
Gotlieb 2012 | VEGF inhibitor | Aflibercept vs. Placebo | 4 mg/kg every 2 weeks | Advanced chemoresistant ovarian cancer and recurrent symp tomatic malignant ascites; ECOG performance status ≤ 2 | 29/26 | 60.0/53.5 | / |
Karlan 2012 | angiopoietin inhibitor | Trebananib + paclitaxel VS. placebo + paclitaxel | 10 mg/kg QW | Recurrent epithelial ovarian (FIGO stage II to IV), fallopian tube, or primary epithelial peritoneal cancer; ECOG performance status 0–1 | 53/55 | 62/59 | 5.5/5.4 |
Pujade-Lauraine 2014 | VEGF inhibitor | Bevacizumab + Chemotherapy vs. Chemotherapy Alone | 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks | Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer; ECOG performance status 0–2 | 179/182 | 62/61 | 13.0/13.9 |
Aghajanian 2015 | VEGF inhibitor | gemcitabine + carboplatin + bevacizumab vs. gemcitabine + carboplatin + placebo | 15 mg/kg every 3 weeks | Platinum-sensitive recurrent ovarian cancer (ie, epithelial ovarian, fallopian tube, or primary peritoneal carcinoma); ECOG performance status 0–1 | 242/242 | 60/61 | 9.6/8.4 |
Pignata 2015 | VEGFR inhibitor | Paclitaxel + pazopanib vs. Paclitaxel only | 800 mg daily | Platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer, stage IC–IV according to FIGO criteria; ECOG performance status 0–1 | 37/36 | 56/58 | 16.3/16.1 |
Ledermann 2016 | VEGFR inhibitor | Platinum-based chemotherapy + Cediranib vs. Platinum-based chemotherapy + Placebo | 20 mg once-daily | Platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer after first-line platinumbased chemotherapy; ECOG performance status 0–1 | 164/118 | 62/62 | 19.5/19.5 |
Monk 2016 | angiopoietin inhibitor | Paclitaxel + Trebananib vs. Paclitaxel + Placebo | 15 mg/kg once weekly | Recurrent partially platinum- sensitive or -resistant epithelial ovarian, primary peritoneal or fallopian tube cancer; GOG performance status ≤ 1 | 461/458 | 60/59 | 18/17.5 |
Coleman 2017 | VEGF inhibitor | chemotherapy plus bevacizumab vs. chemotherapy | 15 mg/kg every 3 weeks | Platinum-sensitive, recurrent clinically evident epithelial ovarian, primary peritoneal, or fallopian tube cancer; COG performance status 0–2 | 337/337 | 59.5/60.6 | 49.6/49.6 |
Marth 2017 | angiopoietin inhibitor | pegylated liposomal doxorubicin + Trebananib vs. pegylated liposomal doxorubicin + Placebo | 15 mg/kg every week | Platinum-resistant epithelial ovarian, peritoneal or fallopian tube cancer; ECOG performance status 0–2 | 114/109 | 61/60 | 12.4/12.4 |
Chekerov 2018 | VEGFR inhibitor | Topotecan + sorafenib vs. Topotecan + placebo | 400 mg twice daily on days 6–15, repeated every 21 days | Platinum-resistant ovarian, peritoneal, or fallopian tube cancers; ECOG performance status 0–2 | 83/89 | 59/58 | 11.3/8.7 |
Richardson 2018 | VEGFR inhibitor | Paclitaxel + pazopanib vs. Paclitaxel + Placebo | 800 mg orally daily | Recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer; COG performance status 0–1 | 52/54 | 61/61 | 17.7/17.7 |
Liu 2019 | VEGFR inhibitor | Cediranib + olaparib vs. olaparib | 30 mg daily | relapsed high-grade serous or high-grade endometrioid ovarian cancer or a high-grade histology with a known germline BRCA mutation (gBRCAm); platinum-sensitive disease | 44/46 | 58.1/57.8 | 46/46 |
Pignata 2021 | VEGF inhibitor | carboplatin-based doublet plus bevacizumab vs. carboplatin-based doublet intravenously | 10 mg/kg intravenous every 14 days | FIGO stage IIIB–IV platinum-sensitive ovarian cancer, fallopian tube carcinoma, or peritoneal carcinoma; ECOG performance status 0–2 | 203/203 | 61/60 | 20.1/20.1 |